Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$139.02 USD

139.02
2,609,579

+10.04 (7.78%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $139.00 -0.02 (-0.01%) 5:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Zacks.com featured highlights include: Marine Products, Nutrisystem, Exelixis, Illumina and Baxter

Zacks.com featured highlights include: Marine Products, Nutrisystem, Exelixis, Illumina and Baxter

    Tirthankar Chakraborty headshot

    5 Winning Stocks With Superb Efficiency Level

    A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.

      Zacks.com featured highlights include: Caterpillar, WellCare Health, Intuit, Cardtronics and Illumina

      Zacks.com featured highlights include: Caterpillar, WellCare Health, Intuit, Cardtronics and Illumina

        Perrigo (PRGO) Misses on Earnings in Q1, Reiterates View

        Perrigo (PRGO) misses earnings estimates but exceeds revenue expectations in Q1. The company reiterates its revenue and adjusted earnings outlook for 2018.

          5 Top Stocks Showing Promise of an Earnings Beat

          Bet on five stocks that are likely to outdo earnings estimates.

            Agios (AGIO) Q1 Loss Wider than Expected, Revenues Miss

            Agios (AGIO) incurs wider-than-expected loss and misses revenue estimates in Q1. The first quarter highlights the FDA's acceptance of the NDA for Tibsovo.

              Zacks.com highlights: Illumina, Alarm.com Holdings, Copart and Vanda Pharmaceuticals

              Zacks.com highlights: Illumina, Alarm.com Holdings, Copart and Vanda Pharmaceuticals

                Tirthankar Chakraborty headshot

                4 Top Efficient Stocks to Buy for Stellar Returns

                A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with its price performance.

                  Illumina (ILMN) Beats on Q1 Earnings, Lifts '18 Guidance

                  Illumina's (ILMN) collaboration with Bristol-Myers Squibb and Loxo Oncology are likely to yield results in the near term.

                    Bristol-Myers Reports Positive Data in NSCLC Trial on Opdivo

                    Bristol-Myers Squibb Company (BMY) announced positive results from the phase III trial, CheckMate -078 trial on immuno-oncology drug Opdivo among a predominantly Chinese population.

                      Can Solid Overall Growth Drive Illumina's (ILMN) Q1 Earnings?

                      Illumina (ILMN) expected to gain from strong revenues at Product as well as Service and other segments in Q1.

                        Illumina Banks on Product Launches & Strategic Partnerships

                        Illumina (ILMN) successfully broadens base by enriching its portfolio of sequencing products and building strategic partnerships with therapeutic and diagnostic service providers.

                          Illumina Banks on Strategic Partnerships, Competition Rife

                          Illumina's (ILMN) recently-signed partnership to distribute Thermo Fisher's Ion AmpliSeq technology is encouraging.

                            Illumina (ILMN) Tops Q4 Earnings & Revenues, Issues Guidance

                            Illumina (ILMN) gains from strength in sequencing consumables and instruments as well as microarray portfolios in Q4.

                              Why Illumina (ILMN) Might Surprise This Earnings Season

                              Illumina (ILMN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

                                Illumina's (ILMN) Q4 Earnings to Show Growth in All Lines

                                Illumina (ILMN) expected to gain from strong revenues at Product as well as Service and other revenue segments in Q4.

                                  Illumina (ILMN) Ties Up With Thermo Fisher for Ion AmpliSeq

                                  Illumina (ILMN) consistently tries to enhance NGS platform.

                                    Pacific Biosciences Hurt by Competition in Niche Markets

                                    Pacific Biosciences (PACB) faces cutthroat competition in the niche space. Also, sluggishness in the European markets is a concern.

                                      Illumina (ILMN) Looks Good: Stock Adds 6.9% in Session

                                      Illumina (ILMN) was a big mover last session, as the company saw its shares rise more than 6% on the day amid huge volumes.

                                        Product Innovation Drives Illumina, Downbeat Margins a Woe

                                        Illumina (ILMN) harbors hopes about recent launches like NovaSeq S4 flow cell and reagent kit for its NovaSeq 6000 System. A low margin scenario due to the NovaSeq launch is a concern.

                                          Here's Why You Should Invest in Illumina (ILMN) Stock Now

                                          Illumina (ILMN) banks on product launches and international market prospects.

                                            Mark Vickery headshot

                                            Top Analyst Reports for Home Depot, Boeing & Merck

                                            Today's Research Daily features new research reports on 16 major stocks, including Home Depot (HD), Boeing (BA) and Merck (MRK).

                                              Illumina Introduces NextSeq 550Dx, Updates Use of MiSeqDx

                                              Illumina (ILMN) expands NGS platform. The company has a solid diagnostic NGS portfolio, which includes NextSeq 550Dx and MiSeqDx.

                                                Shire (SHPG) Q3 Earnings Beat, Immunology Franchise Strong

                                                Shire (SHPG) reported better-than-expected third-quarter earnings and also registered strong growth in immunology franchise. Shares were up in response.

                                                  Omnicell (OMCL) Earnings Beat, Revenues Miss Estimates in Q3

                                                  Omnicell (OMCL) witnessed year-over-year growth in revenues on the back of its Medication Adherence segment in Q3.